220731-04-4

Basic information

• Product Name: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI);tert-butyl 5-aminopyridin-2-ylcarbamate;Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester;tert-Butyl (5-aminopyridin-2-yl);tert-Butyl N-(5-aminopyridin-2-yl)carbamate
• CAS NO: 220731-04-4
• Molecular Formula: C₁₀H₁₅N₃O₂
• Molecular Weight: 209.245
• Product Categories: N-BOC
• Mol File: 220731-04-4.mol

Chemical Properties

• Boiling Point: 330.167 °C at 760 mmHg
• Flash Point: 153.479 °C
• Appearance: /
• Density: 1.203 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.19±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(220731-04-4)
• EPA Substance Registry System: Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI)(220731-04-4)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 220731-04-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) is used as a chemical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its unique structure and reactivity make it a valuable component in the development of new pharmaceutical compounds.
Used in Research and Development Labs:
This chemical compound is also commonly used in research and development labs for the synthesis of new pharmaceutical compounds. Its versatility and potential for creating novel drug candidates make it an essential tool in the ongoing pursuit of medical advancements.
It is important to handle and store Carbamic acid, (5-amino-2-pyridinyl)-, 1,1-dimethylethyl ester (9CI) with care, as it can be hazardous if not handled properly. Proper safety measures should be taken to ensure the safe use of this chemical compound in both industrial and laboratory settings.

InChI:InChI=1/C10H15N3O2/c1-10(2,3)15-9(14)13-8-5-4-7(11)6-12-8/h4-6H,11H2,1-3H3,(H,12,13,14)

Upstream product

• 161117-88-0 (tert-butoxy)-N-(5-nitro(2-pyridyl))carboxamide 
• 4214-76-0 5-nitro-pyridin-2-ylamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1361224-53-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1589534-97-3 5-(((3S)-4-(4-(methylsulfinyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-95-1 tert-butyl (5-(((3S)-4-(4-(methylcarbamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1589534-96-2 4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-methylbenzamide 
• 1572927-66-2 1-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)ethanone 
• 1589534-92-8 5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-methylethyl)phenyl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-91-7 5-(((3S)-4-phenyl-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589534-90-6 tert-butyl (5-(((3S)-4-phenyl-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1589535-24-9 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-4-hexyn-2-ol 
• 1589535-23-8 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-4-pentyn-2-ol 
• 1589535-22-7 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1-trifluoro-3-methoxy-2-propanol 
• 1589535-21-6 3-(4-((2S)-4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-4,4,4-trifluoro-3-hydroxybutanenitrile 
• 1589535-16-9 5-(((3S)-4-(4-(S-methylsulfonimidoyl)-phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinamine 
• 1589535-15-8 5-(((3S)-4-(4-(S-cyclopropylsulfonimidoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)-sulfonyl)-2-pyridinamine 

Relevant articles and documents

HETEROARYLAMINOISOQUINOLINES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF

The application is directed to compounds of formula (IA) : and specifically compounds of formula (I) and their salts and solvates, wherein R1, R11, R12, R13, R4, R5, n, A1, A2, and A3 are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where gluco

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 3. Structure-activity relationships within the aryl carbinol region of the N-arylsulfonamido-N′-arylpiperazine series

We have recently reported a novel approach to increase cytosolic glucokinase (GK) levels through the binding of a small molecule to its endogenous inhibitor, glucokinase regulatory protein (GKRP) these initial investigations culminated in the identification of 2-(4-((2S)-4-((6-amino-3- pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3, 3-hexafluoro-2-propanol (1, AMG-3969), a compound that effectively enhanced GK translocation and reduced blood glucose levels in diabetic animals. Herein we report the results of our expanded SAR investigations that focused on modifications to the aryl carbinol group of this series. Guided by the X-ray cocrystal structure of compound 1 bound to hGKRP, we identified several potent GK-GKRP disruptors bearing a diverse set of functionalities in the aryl carbinol region. Among them, sulfoximine and pyridinyl derivatives 24 and 29 possessed excellent potency as well as favorable PK properties. When dosed orally in db/db mice, both compounds significantly lowered fed blood glucose levels (up to 58%).

SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Imidazopyridine derivatives as PI3K inhibitors

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS

New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).

PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY

Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

Novel RGD peptidomimetics embedding 1,2,3-triazole as central scaffold; Synthesis and αvβ 3 integrin affinity

Ten new RGD (Arginine-Glycine-Aspartic acid) peptidomimetics have been synthesized and screened for their affinity to αvβ 3 integrin receptor. Arginine and Aspartic acid mimetic subunits were connected through 1,2,3-triazole as central scaffold by click chemistry, affording the final products with good yields. Among them, compounds 3f-j exhibited high affinity to the receptor,with IC50 in the low nanomolar range, comparable to that of the reference compound Cilengitide.